Streetbeat News

Earnings

FORA

Forian Inc. (NASDAQ:FORA) reported Q4 earnings with an EPS of $-0.01, beating estimates by 67.0% against an expected $-0.03. However, revenue decreased by $2.54 million compared to the same period last year. The company has a history of beating EPS estimates, as seen in previous quarters, which has positively impacted its share price in the past.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:45 pm

FORA

Forian Inc. (NASDAQ:FORA) reported Q4 earnings with a per-share loss of $(0.01), beating the $(0.03) estimate, but missed sales estimates with $5.37M against the expected $5.56M. This represents a significant improvement in earnings compared to last year but a decrease in sales.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 8:42 pm

NAAS

NaaS Technology reported a significant increase in its Q4 revenues, showing a 119% year-over-year growth to reach $9.1 million.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:42 pm

VVOS

Vivos Therapeutics reported Q4 2023 earnings with a GAAP EPS of $(3.05), missing the $(1.91) estimate, and sales of $3.248M, missing the $3.406M estimate. This represents a 17.77% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:42 pm

RDDT

Three Reddit Inc (NYSE:RDDT) executives sold shares during its IPO, missing out on $19M in additional gains as shares soared post-IPO. The sales were part of the IPO process, with shares initially priced at $34. Despite the sales, shares of Reddit fell 14.60% to $49.32 on Thursday. The timing of these sales and the subsequent drop in share price may impact investor perception and the stock's future performance.

Portfolio Pulse from Chris Katje

March 28, 2024 | 8:40 pm

REED

Reed's Inc. reported a Q4 2023 GAAP EPS of $(2.07) and sales of $11.700M, missing the analyst consensus estimate of $14.084M by 16.93%. This represents a 22.21% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:39 pm

AVBP

ArriVent BioPharma reported a FY23 EPS of $(32.38), compared to $(28.90) in FY22. R&D expenses increased to $64.9M, mainly due to furmonertinib trials. G&A expenses rose to $9.7M, attributed to costs of operating as a public company and higher personnel costs. The net loss widened to $69.3M from $37.0M. However, with $150.4M in cash and upcoming IPO proceeds, the company expects to fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:38 pm

OXM

Oxform Industries' shares dropped following disappointing Q4 financial results and bleak Q1 guidance.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:36 pm

SOL

Emeren Group (NYSE:SOL) reported Q4 2023 GAAP EPS of $(0.15), missing the undefined analyst consensus estimate, with sales of $44M also missing the $44.983M estimate. This represents a 71.43% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:36 pm

BGC

BGC Group, Inc. (NASDAQ:BGC) has reaffirmed its revenue and pre-tax adjusted earnings outlook for Q1 2024, as previously stated in its February 14, 2024, financial results press release.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:35 pm